# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and lowers the price tar...
Oppenheimer analyst Matthew Biegler maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target...
US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4...